Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.1,2 The study met its primary endpoint,* with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.1 CARMELINA® also included a key secondary composite endpoint,† showing a similar kidney safety profile compared to placebo.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005553/en/
The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.1 CARMELINA® also showed a similar rate of hospitalisation for heart failure for linagliptin compared to placebo.1
The full results were presented at the 54th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.
“Heart disease is a major complication and the leading cause of death for people living with type 2 diabetes. CARMELINA® adds important new evidence for type 2 diabetes patients at high risk of heart and/or kidney disease, a population that has been underrepresented in other cardiovascular outcome trials, but whom we see in our daily practice. The trial confirmed that linagliptin can be used with confidence in this patient population,” commented Bernard Zinman, M.D., Professor in the Department of Medicine, University of Toronto and Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
In CARMELINA®, cardiovascular events that contributed to the primary endpoint* occurred in 12.4 percent (434 people) of the linagliptin group compared to 12.1 percent (420 people) in the placebo group, demonstrating a similar long-term cardiovascular safety profile in adults with type 2 diabetes.1 Linagliptin also showed a similar long-term kidney safety profile compared to placebo. This was demonstrated on the composite endpoint reflecting declining kidney function† occurring in 9.4 percent (327 people) of the linagliptin group compared to 8.8 percent (306 people) of the placebo group.1
An increase in the risk of hospitalisation for heart failure has been observed in some other cardiovascular outcome trials in diabetes.3,4 In CARMELINA®, this endpoint was pre-specified and assessed thoroughly via adjudication.‡ Hospitalisation for heart failure occurred in 6 percent (209 people) of the linagliptin group compared to 6.5 percent (226) of the placebo group.1 “These results are particularly meaningful given the patient population in CARMELINA, including those most vulnerable to developing heart failure,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim.
“While many guidelines5,6 now recognise the importance of choosing a diabetes treatment with a proven benefit on reducing cardiovascular risk and mortality in people with type 2 diabetes and heart disease, there remains a need for additional glucose-lowering options,” Waheed Jamal pointed out. “CARMELINA® reinforces confidence in linagliptin as an effective and well-tolerated treatment, with a simple dosing regimen for adults with type 2 diabetes.”
“We have created a unique cardiovascular outcome trial programme for linagliptin with two trials — CARMELINA®, whose results are released today, as well as CAROLINA®, which will report initial results in the near future,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “This programme will provide clinical data on the long-term safety profile of linagliptin in a broad range of adults with type 2 diabetes, which reflects patients that doctors see in their daily practice.7”
CARMELINA® is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.2,8 The study was designed to assess the effect of linagliptin (5mg once daily) compared to placebo (both added to standard of care) on cardiovascular outcomes in adults with type 2 diabetes and high cardiovascular risk, the majority of whom also had kidney disease.2,8 This population of people with high risk of cardiovascular and/or kidney disease reflects patients that doctors see in their daily practice.7 Standard of care included both glucose lowering agents and cardiovascular drugs (including antihypertensive and lipid lowering agents).
CARMELINA® was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Compared to other recently reported outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes, CARMELINA® included the highest number of patients with impaired kidney function.§
To learn more about CARMELINA®, please visit: https://www.carmelinatrial.com/
Trajenta® is a one dose, once daily DPP-4 inhibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for adult patients with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.9 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.9-13
About our cardiovascular outcome trials
As cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes,14 cardiovascular safety of all type 2 diabetes treatments is important. Worldwide, most people with type 2 diabetes die of a cardiovascular event.15 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin.16,17
CARMELINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor linagliptin. CAROLINA®,18 will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments — linagliptin and the sulphonylurea glimepiride. This trial includes adults with relatively early type 2 diabetes and increased cardiovascular risk or established complications, with less than optimised blood sugar control. The majority did not yet have heart and kidney disease. The study will report initial results in the near future. CARMELINA® and CAROLINA® will provide clinical data on the long-term safety profile of linagliptin in a broad range of adults with type 2 diabetes, which reflects patients that doctors see in their daily practice.7
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/CARMELINA
* Primary endpoint defined as time to first occurrence of the 3-P MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke)
† Key secondary endpoint defined as time to first occurrence of sustained end stage kidney disease (ESKD), death due to kidney disease, or a sustained decrease in eGFR from baseline of ≥40 percent compared to placebo
‡ Assessed by an independent clinical event committee in a blinded way
§ Glomerular filtration rate below 30 mL/min/m2
Phone: +49 (6132) 77 2012
Lilly Diabetes and Lilly USA
Gregory Andrew Kueterman
Director of Communications
Phone: +1 (317) 432-5195
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Dataiku Raises $101 Million Series C to Transform and Democratize Enterprise AI Globally19.12.2018 18:00 | Tiedote
Dataiku Inc., one of the world’s leading enterprise data science and machine learning platforms, today announced a $101 million Series C funding round led by ICONIQ Capital and supported by Alven Capital, Battery Ventures, Dawn Capital, and FirstMark Capital. This announcement follows the company’s $28 million Series B in September 2017 and the release of Dataiku 5 in September 2018. Since its founding in 2013, Dataiku has focused on the vision of democratized data science as the key to uninhibited possibilities instead of restricted technologies reserved for the elite few. Today, Dataiku provides a platform that enables enterprises to fundamentally transform their business - global leaders use it to build AI that optimizes marketing budget, enables maintenance services, anticipate market trends or detects fraud, and more. “We’re very excited about what this latest funding round represents - it’s a confirmation of our vision to build and deliver the missing block for the modern enterpr
Universal Laser Systems Expands Its Materials Database with AOK Technologies, Solvay and 3M Materials19.12.2018 16:05 | Tiedote
Universal Laser Systems (ULS) announces the addition of AOK Technologies, Solvay and 3M™ materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The AOK Technologies, Solvay, and 3M materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: AOK Technologies TCK6 Thermally Conductive Insulator AOK Technologies TC1200 Thermally Conductive Insulator Solvay Udel® P-1700 Polysulfone (PSU) Solvay Ajedium™ Film Ultem® 1000-1000 Polyetherimide (PEI) 3M™ 1538L Rayon Acetate Woven Fabric Medical Tape Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advanta
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases19.12.2018 16:01 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005363/en/ Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be resp
Boeing-Leonardo Team Selects FLIR Systems EO/IR Surveillance Sensors for US Strategic Command UH-1N Replacement Contract19.12.2018 16:00 | Tiedote
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been selected by Boeing to provide the FLIR Star SAFIRE 380-HDc EO/IR surveillance sensor for the United States Air Force (USAF) UH-1N replacement contract. The replacement program will replace the current fleet of USAF UH-1N helicopters, which support the service’s nuclear intercontinental ballistic missile bases in Wyoming, Montana and North Dakota. The aircraft will also be used for training, test and operational support airlift missions. The initial contract award to FLIR is for the first four helicopters, with the total contract up to 84 MH-139 helicopters and valued at more than $40 million to FLIR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005203/en/ FLIR will provide its Star SAFIRE 380-HDc airborne surveillance camera as part of the Boeing-Leonardo UH-1N replacement contract (Photo: Business Wire) Boeing was awarded a $375.5 million firm-fixed-price
BOC Group Listed as a Representative Vendor in the 2018 Gartner Market Guide for Enterprise Business Process Analysis19.12.2018 15:00 | Tiedote
The leading global provider of Enterprise Management Solutions, BOC Group, is pleased to share its recognition for its BPM suite ADONIS NP, in Gartner's latest Market Guide for Enterprise Business Process Analysis * . Thereby, BOC Group continues its recognition from the October 2018 Gartner Magic Quadrant and Critical Capabilities for Enterprise Architecture Tools reports for its EA suite ADOIT. Tobias Rausch, ADONIS product manager comments: “We are happy about getting recognized by Gartner, for the second time now, in their recently published Market Guide for Enterprise Business Process Analysis report. We see our placement in this year’s Market Guide as a testimony to our cutting-edge Business Process Analysis offering, and a validation that our strong focus on BPA is helping businesses in the digital transformation of their enterprise.” The Business Transformation Suite ADONIS NP is BOC Group's flagship product and Business Process Management and Analysis tool. This fully web-base
Slice Launch Studio Opens to Insurers and Tech Companies to Create Digital Insurance Products19.12.2018 15:00 | Tiedote
Slice Labs Inc., a leading on-demand insurance cloud platform provider, announced today the opening of the Slice Launch Studio in downtown Toronto, which is designed to be an innovation hub for Slice and its partners to ideate, experiment, test and deploy new on-demand insurance products on the Slice Insurance Cloud Services (ICS) platform. Insurers and technology companies from around the world can come to the Launch Studio to collaborate on Hackathons, a key step in Slice’s approach to getting product to market quickly. Slice will also host events year-round, bringing together thought leaders from across the globe to discuss and address emerging and increasing risks. Slice is currently working with insurers in the U.S., Canada, UK and SE Asia to launch new on-demand insurance products, using a minimum viable product methodology which allows for launch in under three months. The Co-operators Group is the pilot partner for the Launch Studio, who recently launched duuo, both its new dig
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme